Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

circular RNAs 0000515 and 0011385 as potential biomarkers for disease monitoring and determining prognosis in pancreatic ductal adenocarcinoma.

Authors:
Hanqing Wu Bo Wang Li Wang Yinkai Xue

Oncol Lett 2022 Feb 21;23(2):56. Epub 2021 Dec 21.

Department of Emergency Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China.

Pancreatic ductal adenocarcinoma (PDAC) is extremely fatal and potential biomarkers for precision medicine of patients with PDAC are yet to be elucidated. Moreover, the clinical values of circular RNAs (circRNAs) in PDAC management are yet to be investigated. The aim of the present study was to perform a secondary analysis of two PDAC public datasets (GSE69362 and GSE79634), to identify the candidate circRNAs, to validate the expression of these circRNAs, and to determine their association with the clinicopathological characteristics and survival of patients with PDAC. A total of 60 patients with PDAC were retrospectively reviewed in the present study. The expression levels of these candidate circRNAs were detected in PDAC tissues and paired adjacent normal tissues via reverse transcription-quantitative PCR analysis. In addition, the clinicopathological characteristics and overall survival (OS) of patients with PDAC were recorded. Bioinformatics analysis identified 22 overlapping differentially expressed (DE) circRNAs between the GSE69362 and GSE79634 datasets, among which nine DEcircRNAs with accordant expression trends (the DEcircRNAs that were upregulated or downregulated in tumor tissues compared with paired adjacent normal tissues in both datasets) were selected as candidate circRNAs, including circ_0000515, circ_0000517, circ_0000520, circ_0000514, circ_0011385, circ_0055033, circ_0072088, circ_0003528 and circ_0008514. In the 60 patients with PDAC, the expression levels of circ_0000515, circ_0000517, circ_0000520, circ_0000514, circ_0011385, circ_0055033, circ_0072088 and circ_0003528 were notably upregulated in PDAC tissues compared with paired adjacent normal tissues. Furthermore, circ_0000515, circ_0000520, circ_0000514, circ_0011385 and circ_0072088 were positively associated with T stage, N stage and/or TNM stage in patients with PDAC. Notably, circ_0000515 and circ_0011385 were negatively associated with OS in patients with PDAC. Taken together, the results of the present study suggest that circ_0000515 and circ_0011385 may serve as prognostic biomarkers for patients with PDAC.

Download full-text PDF

 Source
http://dx.doi.org/10.3892/ol.2021.13174DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721853PMC
February 2022

Publication Analysis

Top Keywords

patients pdac
32
pdac
13
circ_0000520 circ_0000514
12
candidate circrnas
12
circ_0000514 circ_0011385
12
normal tissues
12
adjacent normal
12
paired adjacent
12
circ_0000517 circ_0000520
8
circ_0000515 circ_0000517
8
ductal adenocarcinoma
8
pancreatic ductal
8
circ_0011385 circ_0055033
8
circular rnas
8
pdac tissues
8
expression levels
8
circ_0055033 circ_0072088
8
patients
8
survival patients
8
characteristics survival
8

Keyword Occurance

Similar Publications

Assessment of the external validity of the National Comprehensive Cancer Network (NCCN) guidelines for pancreatic ductal adenocarcinoma in a population of older patients aged 70 years and older.

Authors:
Maria Grazia Rodriquenz Juan-Pablo Negrete-Najar Christine Sam Marina Sehovic Martine Extermann

J Geriatr Oncol 2022 May 18. Epub 2022 May 18.

Moffitt Cancer Center, Florida, USA.

Introduction: Pancreatic ductal adenocarcinoma (PDAC) mainly occurs in older adults. Since randomized clinical trials (RCTs) provide the highest-quality evidence incorporated in NCCN recommendations, the underrepresentation of older patients in RCTs challenges guidelines' external validity and limits the solidity of evidence in this specific population.

Materials And Methods: The study aimed to investigate external validity of NCCN guidelines for PDCA and the impact of reference studies eligibility on overall survival (OS) in a real-world older population. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Contrast-enhanced ultrasound of solid pancreatic head lesions: a prospective study.

Authors:
Pankaj Gupta Pratyaksha Rana Yashi Marodia Jayanta Samanta Vishal Sharma Saroj K Sinha Harjeet Singh Vikas Gupta Thakur Deen Yadav Radhika Sreenivasan Kim Vaiphei Arvind Rajwanshi Rakesh Kochhar Manavjit Sandhu

Eur Radiol 2022 May 19. Epub 2022 May 19.

Department of Radiodiagnosis and Imaging, PGIMER, Chandigarh, India.

Objective: To evaluate the role of contrast-enhanced ultrasound (CEUS) in the differential diagnosis of solid pancreatic head lesions (SPHL).

Methods: This prospective study comprised consecutive patients with SPHL who underwent CEUS evaluation of the pancreas. Findings recorded at CEUS were enhancement patterns (degree, completeness, centripetal enhancement, and percentage enhancement) and presence of central vessels. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Bacterial lipopolysaccharide as a negative predictor of adjuvant gemcitabine efficacy in pancreatic cancer.

Authors:
Michael Guenther Lina Gil Sai Agash Surendran Melanie Alexandra Palm Volker Heinemann Michael von Bergwelt-Baildon Julia Mayerle Jutta Engel Jens Werner Stefan Boeck Steffen Ormanns

JNCI Cancer Spectr 2022 May 19. Epub 2022 May 19.

Institute of Pathology, Faculty of Medicine, Ludwig-Maximilians-University, Munich, Germany.

Adjuvant gemcitabine is one standard of care after pancreatic ductal adenocarcinoma (PDAC) resection. No biomarker for its efficacy is established. As bacteria mediate gemcitabine resistance, we analyzed whether lipopolysaccharide (LPS) as surrogate for bacterial colonization is prognostic in PDAC patients treated with (aGC) or without (naGC) adjuvant gemcitabine. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Efficacy and Safety of Neoadjuvant Chemoradiation Therapy Administered for 5 Versus 2 Weeks for Resectable and Borderline Resectable Pancreatic Cancer.

Authors:
Hironobu Suto Keiichi Okano Minoru Oshima Yasuhisa Ando Hiroyuki Matsukawa Shigeo Takahashi Toru Shibata Hideki Kamada Hideki Kobara Akihito Tsuji Tsutomu Masaki Yasuyuki Suzuki

Pancreas 2022 Mar;51(3):269-277

From the Departments of Gastroenterological Surgery.

Objectives: Indications of preoperative treatment for resectable (R-) or borderline resectable (BR-) pancreatic ductal adenocarcinoma (PDAC) are unclear, and the protocol remains to be standardized.

Methods: Included 65 patients with R- and BR-PDAC with venous involvement (V-) received neoadjuvant chemoradiotherapy with S-1 and 50 Gy of radiation as the 5-week regimen. The outcomes of this group were compared with those of 52 patients who underwent S-1 and 30 Gy of radiation as the 2-week regimen, previously collected as our prospective phase II study. Read More

View Article and Full-Text PDF
March 2022
Similar Publications

Hedgehog Signaling Pathway Proteins in Prognosis of Pancreatic Ductal Adenocarcinoma and Its Differentiation From Chronic Pancreatitis.

Authors:
Katarzyna Winter Monika Dzieniecka Janusz Strzelczyk Małgorzata Wągrowska-Danilewicz Marian Danilewicz Hubert Zatorski Ewa Małecka-Wojciesko

Pancreas 2022 Mar;51(3):219-227

From the Department of Digestive Tract Diseases, Medical University of Lodz, Lodz, Poland.

Objectives: The Hedgehog signaling pathway (Hh) probably plays a role in development and progression of pancreatic ductal adenocarcinoma (PDAC).

Methods: In our study, 114 patients (83 with PDAC and 31 with chronic pancreatitis [CP]) after pancreatic surgery were enrolled. The immunoexpression of Sonic hedgehog (Shh), Smoothened (Smo), and Glioblastoma transcription factor 1 (Gli1) and Ki-67 were detected in tissue specimens. Read More

View Article and Full-Text PDF
March 2022
Similar Publications
}